Image in cardiology

Biodegradable drug eluting stents: invasive and non-invasive imaging


Neville Kukreja
Neville Kukreja, MA, MRCP; Masato Otsuka, MD; Carlos van Mieghem, MD; Jurgen Ligthart, BSc; Georgios Sianos, MD PhD; Patrick W. Serruys*, MD, PhD
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
A biodegradable everolimus-eluting stent, developed by Bioabsorbable Vascular Solutions, Inc., an affiliate of Abbott Laboratories, located in Mountain View, CA, is currently undergoing clinical evaluation. The stent consists of a Polylactic acid (PLA) stent backbone processed for increased radial strength to provide stent integrity and a thin amorphous everolimus/PLA matrix coating (1:1 ratio of Everolimus/PLA matrix) for controlled drug release. Panel (a) shows the stent ex vivo: the stent is transparent apart from 2 radio-opaque markers at both proximal and distal edges. The appearances on optical coherence tomography (OCT) (Panel b) are quite unlike conventional stents; OCT can detect the ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
The future of European percutaneous cardiovascular interventions

Latest news